According to a recent press release, “IOMICS announced the release of its first cloud-deployed analytics service, ASPEN, based on the award-winning FUSION Analytics Platform. ASPEN allows every bench scientist to automatically mine and model complex multiscale datasets to identify molecular signatures of pathogenic processes and disease progression critical to drug development, companion diagnostics, and personalized patient profiling. ‘The pace and complexity of biological research is increasing rapidly. For some diseases we have become data rich, yet obtaining actionable information from these complex data sets remains a challenge,’ said J. Gormley, consulting CTO and senior software architect at IOMICS. ‘To maintain progress, and to support the growing number of precision medicine initiatives worldwide, researchers must be willing to embrace new methods and new computational models optimized for chemical and omic data sets. This requires cognitive computing techniques which by definition employ algorithms and data in a smart, adaptive and synergistic way’.”
The release continues, “ASPEN is a feature-rich in silico model building and hypothesis discovery service that allows a bench scientist to perform real-time specification-based data staging and predictive model development for a broad range of chemical characterization, biomarker discovery, and drug development initiatives. ASPEN is the only solution that seamlessly combines chemical and molecular data staging, predictive model creation, validation, and performance reporting, along with realtime pathway analysis and automated evidence summaries, all in one integrated service. For high-throughput experiments, ASPEN also provides options for linking with NGS technologies, high-complexity assays, and digital instrumentation for both automated and continuous analysis and process characterization. ASPEN can evaluate a broad range of candidate biomarkers for their predictive value at multiple scales of interest including compound toxicity, molecular function, cellular process and clinical endpoints.”
Read more at PR Web.
Image used under license from Shutterstock.com